Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878126 | 0.80 | DPP4 (0.39) | DPP4DPP8DPP9ACEMMP13 | |
| SCHEMBL18885945 | 0.78 | HTT (0.43) | DPP4TSHRPARP1ADORA2AKMT2A | |
| SCHEMBL24469641 | 0.77 | PARP1 (0.38) | DPP4PARP1ADORA2AKMT2ACYP3A4 | |
| SCHEMBL30830155 | 0.77 | PARP1 (0.38) | DPP4PARP1ADORA2AKMT2ACYP3A4 | |
| SCHEMBL18882839 | 0.75 | ADORA2A (0.39) | TSHRKDM4EADORA2AKMT2AAPEX1 | |
| SCHEMBL18863330 | 0.75 | KAT2B (0.40) | TSHRPARP1KMT2AMEN1POLB | |
| SCHEMBL23089311 | 0.75 | ADORA2A (0.36) | KDM4EADORA2AKMT2AMEN1POLB | |
| SCHEMBL12714330 | 0.74 | PARP1 (0.51) | PARP1LMNAPARP2 | |
| SCHEMBL18863190 | 0.73 | DPP4 (0.31) | DPP4DPP8PARP1CYP3A4LMNA | |
| SCHEMBL18863718 | 0.72 | DPP4 (0.36) | DPP4DPP8DPP9ACEMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009911-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11040960-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3377059-B1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200140418-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10370363-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180170916-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170916-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-9809581-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809581-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009911-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | DPP4 2511/4885DPP8 779/4885DPP9 960/4885 |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | DPP4 2511/4885DPP8 779/4885DPP9 960/4885 |
| US-20200140418-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | DPP4 2511/4885DPP8 779/4885DPP9 960/4885 |
| US-10370363-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | DPP4 2511/4885DPP8 779/4885DPP9 960/4885 |
| US-11040960-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | DPP4 2511/4885DPP8 779/4885DPP9 960/4885 |
| US-20180170916-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | DPP4 2514/4885DPP8 781/4885DPP9 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.